London Co. of Virginia Has $97.75 Million Position in Bruker Corporation $BRKR

London Co. of Virginia cut its holdings in Bruker Corporation (NASDAQ:BRKR) by 25.2% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 3,008,493 shares of the medical research company’s stock after selling 1,015,320 shares during the period. London Co. of Virginia owned approximately 1.98% of Bruker worth $97,746,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. Spire Wealth Management grew its stake in Bruker by 85.3% during the third quarter. Spire Wealth Management now owns 1,445 shares of the medical research company’s stock worth $47,000 after purchasing an additional 665 shares during the period. Jones Financial Companies Lllp lifted its stake in Bruker by 79.7% in the third quarter. Jones Financial Companies Lllp now owns 2,773 shares of the medical research company’s stock valued at $86,000 after buying an additional 1,230 shares during the period. Elevation Point Wealth Partners LLC acquired a new position in Bruker in the second quarter valued at approximately $87,000. EverSource Wealth Advisors LLC boosted its holdings in shares of Bruker by 51.5% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 2,770 shares of the medical research company’s stock worth $114,000 after buying an additional 942 shares in the last quarter. Finally, Nisa Investment Advisors LLC grew its position in shares of Bruker by 727.9% during the 3rd quarter. Nisa Investment Advisors LLC now owns 5,100 shares of the medical research company’s stock worth $166,000 after buying an additional 4,484 shares during the period. 79.52% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

BRKR has been the subject of several research analyst reports. Zacks Research upgraded shares of Bruker from a “strong sell” rating to a “hold” rating in a research note on Monday, December 8th. Citigroup cut their target price on shares of Bruker from $53.00 to $40.00 and set a “neutral” rating on the stock in a research note on Friday, February 13th. JPMorgan Chase & Co. lifted their price target on shares of Bruker from $50.00 to $55.00 and gave the company an “overweight” rating in a research note on Monday, December 15th. UBS Group reiterated a “neutral” rating and set a $49.00 price objective on shares of Bruker in a report on Friday, February 13th. Finally, TD Cowen cut their price objective on shares of Bruker from $53.00 to $43.00 and set a “hold” rating on the stock in a research report on Friday, February 13th. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, five have given a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $50.38.

Bruker Price Performance

Shares of NASDAQ BRKR opened at $32.76 on Tuesday. The stock has a market cap of $4.99 billion, a price-to-earnings ratio of -218.40, a PEG ratio of 2.02 and a beta of 1.19. The company has a debt-to-equity ratio of 0.75, a quick ratio of 0.87 and a current ratio of 1.73. Bruker Corporation has a fifty-two week low of $28.53 and a fifty-two week high of $56.22. The firm’s 50-day simple moving average is $43.13 and its 200 day simple moving average is $41.11.

Bruker (NASDAQ:BRKR) last issued its quarterly earnings data on Thursday, February 12th. The medical research company reported $0.59 EPS for the quarter, missing analysts’ consensus estimates of $0.65 by ($0.06). Bruker had a positive return on equity of 13.56% and a negative net margin of 0.25%.The company had revenue of $977.20 million for the quarter, compared to the consensus estimate of $964.61 million. During the same period in the prior year, the firm posted $0.76 earnings per share. The business’s revenue for the quarter was down .2% on a year-over-year basis. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. As a group, research analysts anticipate that Bruker Corporation will post 2.69 earnings per share for the current fiscal year.

Bruker Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, April 7th. Investors of record on Monday, March 23rd will be issued a dividend of $0.05 per share. The ex-dividend date is Monday, March 23rd. This represents a $0.20 annualized dividend and a yield of 0.6%. Bruker’s dividend payout ratio is -133.33%.

Insider Buying and Selling

In other Bruker news, VP Mark Munch sold 2,000 shares of the firm’s stock in a transaction on Friday, March 13th. The stock was sold at an average price of $35.44, for a total transaction of $70,880.00. Following the transaction, the vice president directly owned 128,443 shares in the company, valued at approximately $4,552,019.92. This trade represents a 1.53% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Over the last ninety days, insiders sold 11,000 shares of company stock valued at $554,280. Corporate insiders own 27.30% of the company’s stock.

Bruker Profile

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.